• BioMarin Reviews Status of Exon 51 Composition of Matter and Method of Use Patent Interference Cases against Sarepta Therapeutics

    Source: Nasdaq GlobeNewswire / 21 Sep 2016 13:54:15   Europe/London

    N/A
Share on,